Back to Search
Start Over
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib
- Source :
- Journal of cancer research and clinical oncology. 146(10)
- Publication Year :
- 2020
-
Abstract
- Purpose Sorafenib is an oral tyrosine kinase inhibitor (TKI) and first-line treatment option for advanced hepatocellular carcinoma (HCC). Preliminary evidence indicates proton pump inhibitors (PPI) may affect the absorption of TKIs through decreased gut dissolution. This study aims to evaluate the impact of PPI use on the survival outcomes of advanced HCC patients treated with sorafenib. Methods The study was a secondary analysis of individual-participant data from the phase III clinical trial NCT00699374. Cox proportional hazard analysis was used to evaluate the association between baseline PPI use and survival outcomes. Overall survival (OS) was the primary outcome with progression-free survival (PFS) secondary. Results In a cohort of 542 advanced HCC patients initiating sorafenib treatment, 122 were concomitantly using a PPI at baseline. No significant associations between baseline PPI use and OS were identified on univariable (HR [95% CI]; 1.01 [0.80-1.28], P = 0.93) and adjusted (1.10 [0.82-1.41], P = 0.62) analysis. Furthermore, no significant associations between baseline PPI use and PFS were identified on univariable (0.96 [0.76-1.21], P = 0.73) and adjusted (1.11 [0.86-1.44], P = 0.41) analysis. Conclusion In a large high-quality dataset, PPI use was not observed to compromise the survival outcomes of advanced HCC patients initiated on sorafenib. Refereed/Peer-reviewed
- Subjects :
- 0301 basic medicine
Oncology
Sorafenib
Cancer Research
medicine.medical_specialty
Carcinoma, Hepatocellular
medicine.drug_class
Kaplan-Meier Estimate
Tyrosine-kinase inhibitor
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Primary outcome
Secondary analysis
Internal medicine
Medicine
Humans
Protein Kinase Inhibitors
Proportional Hazards Models
Hematology
business.industry
Liver Neoplasms
Drug Synergism
Proton Pump Inhibitors
General Medicine
medicine.disease
digestive system diseases
Progression-Free Survival
Clinical trial
Survival Rate
030104 developmental biology
Clinical Trials, Phase III as Topic
Gastrointestinal Absorption
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Cohort
business
medicine.drug
Subjects
Details
- ISSN :
- 14321335
- Volume :
- 146
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Journal of cancer research and clinical oncology
- Accession number :
- edsair.doi.dedup.....417791fc51ed40f81521ad6221702559